Brief: Vertex Pharmaceuticals Exec Says Cystic Fibrosis Portfolio Has About 9% Exposure To Medicare And About 23% Exposure To Medicaid - Goldman Sachs Conference
10/06/2025 20:17
Vertex Pharmaceuticals Inc VRTX.O: VERTEX PHARMACEUTICALS EXEC SAYS CYSTIC FIBROSIS PORTFOLIO HAS ABOUT 9% EXPOSURE TO MEDICARE AND ABOUT 23% EXPOSURE TO MEDICAID - GOLDMAN SACHS CONFERENCE VERTEX PHARMACEUTICALS EXEC SAYS LARGER HOSPITALS HAVE ADDED JOURNAVX TO THEIR FORMULARY AND EXPECT MORE IN H2 2025 Source text: [ID:] Further company coverage: VRTX.O
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31